ライフサイエンスコーパス: protective efficacy

1 ponse is considered critical for HIV vaccine protective efficacy.

2 um salts may not be potent enough to achieve protective efficacy.

3 tors has an impact on the memory profile and protective efficacy.

4 vaccines because of high immunogenicity and protective efficacy.

5 c fitness, longevity, polyfunctionality, and protective efficacy.

6 y the rBCG vaccine candidate relevant to its protective efficacy.

7 ning CS may result in a significant clinical protective efficacy.

8 ovel combination of antibodies with enhanced protective efficacy.

9 wild-type H7N9 virus to assess the vaccine's protective efficacy.

10 d in augmented immune responses and improved protective efficacy.

11 en 85B further enhances immune responses and protective efficacy.

12 ed, this singular approach can yield limited protective efficacy.

13 eportedly erodes proliferative potential and protective efficacy.

14 faster, to higher titers, and with improved protective efficacy.

15 didate that enhances both TH1 generation and protective efficacy.

16 tant role than others in determining vaccine protective efficacy.

17 with long interdose periods and provides low protective efficacy.

18 monstrate emergent properties with regard to protective efficacy.

19 e, however, not yet matched whole sporozoite protective efficacy.

20 red the mucosal immune responses and vaccine protective efficacy.

21 minidase (NA) have to be updated for optimal protective efficacy.

22 nt isotypes manifest profound differences in protective efficacy.

23 ficant antigen-sparing effects with improved protective efficacy.

24 imal to evaluate immunogenicity, safety, and protective efficacy.

25 monstrated high levels of pre- and post-CHMI protective efficacy.

26 t G further increased its immunogenicity and protective efficacy.

27 dered for vaccine designs to achieve optimal protective efficacy.

28 TSV DNA vaccine, its immunogenicity, and its protective efficacy.

29 at Fc-dependent effector function determines protective efficacy.

30 livery of nucleic acid immunogens to improve protective efficacy.

31 require two or three immunisations for full protective efficacy.

32 nctional mechanism for their contribution to protective efficacy.

33 [16%] of 337 women vs 60 [18%] of 329 women; protective efficacy 12% [95% CI -23 to 37], p=0.45).

34 ar responses during vaccination may maximize protective efficacy across all DENV serotypes.

35 The protective efficacy afforded by anti-A33 MAb was compara

36 acity of the boosting antigen influences the protective efficacy afforded by prime-boost vaccine regi

37 he detailed kinetics of immune responses and protective efficacy after a single intranasal immunizati

38 We also noted significant cross-protective efficacy against 6-month persistent infection

39 c--and were evaluated for immunogenicity and protective efficacy against a highly lethal intraperiton

40 xture of CD4-CD8 lipopeptide vaccine and the protective efficacy against acute virus replication and

41 hese candidate vaccine strains showed strong protective efficacy against AHSV infection in an IFNAR(-

42 The primary endpoint was protective efficacy against all episodes of clinical mal

43 argeting three arenaviruses and demonstrated protective efficacy against all three targets.

44 No regimen had any protective efficacy against anaemia or hospital admissio

45 on of primary prostatic tumor and also shows protective efficacy against angiogenesis and late stage

46 CD4(+) T cell responses are associated with protective efficacy against blood-stage malaria, whereas

47 abbit antibody to PMA-FLA showed evidence of protective efficacy against both types of this organism

48 n chi9241 also induced significantly greater protective efficacy against challenge with virulent S. p

49 ein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria

50 cine that affords in the neighborhood of 50% protective efficacy against clinical malaria is in the l

51 hich is a notable achievement, its long-term protective efficacy against each of the 4 dengue virus s

52 i-GP antibody responses and further improved protective efficacy against Ebola virus infection.

53 nal improvement relative to its precursor in protective efficacy against EBOV and SUDV in guinea pigs

54 age antigen(s) alone has induced significant protective efficacy against erythrocytic-stage infection

55 nes demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets an

56 It induces sterile protective efficacy against heterologous strain sporozoi

57 he only vaccine approach shown to elicit any protective efficacy against HIV-1 acquisition is based o

58 evels and cellular immune responses, and the protective efficacy against homologous and heterologous

59 le of inducing cellular immune responses and protective efficacy against intracellular pathogens.

60 ) CFU with the mutant to evaluate safety and protective efficacy against intraperitoneal and aerosol

61 ole in attenuating diarrhea and in providing protective efficacy against intraperitoneal Shigella inf

62 The essential oil showed mutagen-protective efficacy against IQ and MeIQ tested as direct

63 CD47KO mice with vaccination showed greater protective efficacy against lethal challenge, as evidenc

64 tested using opsonophagocytic assays and for protective efficacy against lethal peritonitis in mice.

65 pigs, metformin enhances immunogenicity and protective efficacy against M. tuberculosis challenge.

66 Protective efficacy against malaria, compared with daily

67 quine encephalitis virus (VEEV) demonstrated protective efficacy against Marburg virus in nonhuman pr

68 These findings demonstrate that NDV-3 protective efficacy against MRSA in SSSI involves a robu

69 s an urgent need for therapeutics with broad protective efficacy against multiple filoviruses.

70 sity on vaccine-induced immune responses and protective efficacy against pandemic H1N1 influenza viru

71 y CD8+ T cell quantity and quality determine protective efficacy against reinfection.

72 Protective efficacy against RSV challenge was not reduce

73 ificantly improved vector immunogenicity and protective efficacy against RSV.

74 iola virus homologues might exhibit improved protective efficacy against smallpox.

75 Our primary objective was to assess protective efficacy against symptomatic, virologically c

76 These data show protective efficacy against the most pathogenic Angola s

77 antibody affinity maturation, improving its protective efficacy against three Ebolaviruses: EBOV, SU

78 ent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses.

79 ly, the mutant's virulence potential and its protective efficacy against type A and type B strains we

80 , diminished antibody responses, and reduced protective efficacy against wild-type virus challenge fo

81 Protective efficacy also significantly differed between

82 ults in a vaccine with a 20-fold decrease in protective efficacy and a 10,000-fold increase in safety

83 effectiveness has been hindered by variable protective efficacy and a lack of lasting memory respons

84 s, given different assumptions regarding the protective efficacy and duration of the adaptive immune

85 Coxiella burnetii infection, we compared the protective efficacy and immunogenicity between formalin-

86 In this study, we assessed the protective efficacy and immunogenicity of a multisubunit

87 e skin using a microneedle patch can improve protective efficacy and induce long-term sustained immun

88 nt quantity can be achieved while maximizing protective efficacy and preserving proliferative potenti

89 ) (VRC-10-332) that demonstrated substantial protective efficacy and revealed a genetic signature of

90 We assessed the protective efficacy and safety of prolonging co-trimoxaz

91 the scarcity of pre-clinical models to test protective efficacy and support further clinical trials.

92 double-knockout Pbuis3(-)/4(-) parasites for protective efficacy and the contribution of CD8(+) T cel

93 et because of its documented immunogenicity, protective efficacy, and antifecundity effects observed

94 s, and the extent of attenuation and induced protective efficacy are not readily available.

95 enicity in M. tuberculosis-naive animals and protective efficacy as measured by a reduction in lung M

96 ciparum (Pf) sporozoites (PfSPZ Vaccine) and protective efficacy assessed by homologous controlled hu

97 infected cells, contributes substantially to protective efficacy at early and late time points postim

98 To estimate the protective efficacy, BALB/c mice were given three inject

99 ew and improved BCG strain which retains its protective efficacy but is diagnostically compatible wit

100 d PfLSAP2, and investigated the induction of protective efficacy by coadministration of single-antige

101 mune sera significantly enhanced the passive protective efficacy by fully protecting mice against let

102 lective TLR ligand combinations can increase protective efficacy by increasing the quality rather tha

103 Ongoing studies will determine whether protective efficacy can be enhanced by additional altera

104 novel cocktails of antibodies with enhanced protective efficacy compared to individual MAbs.

105 ssing PfLSA1 or PfLSAP2 was shown to improve protective efficacy compared to vaccination with each si

106 serogroups were associated with the highest protective efficacy compared to vaccines with fewer comp

107 Protective efficacy correlated with the functionality of

108 For wild-type mice, protective efficacy corresponded to increased infiltrati

109 activity of the elicited antibodies, and the protective efficacy elicited in mice immunized with the

110 re primarily non-neutralizing and had modest protective efficacy following passive transfer.

111 ent (residual insecticidal activity) and (2) protective efficacy for volunteers sleeping under the LL

112 The protective efficacy generated by immunization with this

113 opulation characteristics that may relate to protective efficacy have received little attention.

114 ch anti-HIV-1 envelope Abs can contribute to protective efficacy.IMPORTANCE Anti-V2 antibodies (Abs)

115 , and desiccation, were determined and their protective efficacies in animals confirmed.

116 nstructural protein 1 (NS1) have shown broad protective efficacies in birds and mammals, which correl

117 terleukin-17 secretion and provided a higher protective efficacy in a mouse challenge model than did

118 d SEA and demonstrate its immunogenicity and protective efficacy in a mouse model of toxic shock.

119 types and reported preliminary data on their protective efficacy in animals.

120 children support its further assessment for protective efficacy in children in enterotoxigenic E col

121 V glycoproteins for their immunogenicity and protective efficacy in cotton rats and African green mon

122 GCP-rCpa1 vaccine had significantly reduced protective efficacy in Dectin-1 (-/-), Dectin-2 (-/-), a

123 vaccine candidate, which showed significant protective efficacy in endemic populations in Guinea.

124 date vaccines were immunogenic and exhibited protective efficacy in ferrets.

125 with AS04 has the potential to provide broad protective efficacy in human subjects.

126 essential to achieve immediate and sustained protective efficacy in humans.

127 ests that the bivalent HPV-16/18 vaccine has protective efficacy in men.

128 lts demonstrated safety, immunogenicity, and protective efficacy in mice and nonhuman primates (NHPs)

129 within the envelope glycoprotein and exhibit protective efficacy in mice.

130 cific antibodies and compromised the vaccine protective efficacy in mice.

131 icity, opsonic killing activity, and passive protective efficacy in mice.

132 the gastrointestinal mucosa and for vaccine protective efficacy in mice.

133 evaluated for virulence, immunogenicity, and protective efficacy in mice.

134 bition of RSV infection and propagation, and protective efficacy in mice.

135 own ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infect

136 tional analogs of P7C3 correlates with their protective efficacy in MPTP-mediated neurotoxicity.

137 This trial compared the protective efficacy in older adults of a quadrivalent, r

138 experiments proved this vaccine candidate's protective efficacy in pigs and the promise to control c

139 Candidate ZIKV vaccines have shown protective efficacy in preclinical studies carried out i

140 s study, we evaluated the immunogenicity and protective efficacy in rabbits of multiple antigenic pep

141 We tested the immunogenicity and protective efficacy in rhesus macaques of one dose of MV

142 oproteins (VSVDeltaG/Dual) and evaluated its protective efficacy in the common lethal Syrian hamster

143 ing whether there may, or may not, have been protective efficacy in the RV144 vaccine trial have impo

144 er of immunizations with CTB could influence protective efficacy in the suckling mouse model of chole

145 irus vectors afforded substantially improved protective efficacy in this challenge model.

146 We then tested its protective efficacy in two animal models, mice and guine

147 tudy, we investigated the immunogenicity and protective efficacy, in the guinea pig model of recurren

148 on with the recombinant Ad5/3 vector induces protective efficacy indistinguishable from that elicited

149 This protective efficacy is estimated to result from a 96.1%

150 Although both vaccines demonstrated cross-protective efficacy, LAIV induced higher levels of nasal

151 To demonstrate feasibility and protective efficacy, nucleoside-modified mRNAs encoding

152 We found that the loss of protective efficacy observed with FW/50 was associated w

153 with P. berghei sporozoites to determine the protective efficacies of different vaccine regimens.

154 CM-2 retains immunogenicity, we compared the protective efficacies of formalin-inactivated C. burneti

155 onatal gnotobiotic pig model to evaluate the protective efficacies of primary infection, P particles,

156 comparison of the immunogenic properties and protective efficacies of the different forms of hRSV F w

157 This provided a ranking of the protective efficacies of the initial panel of intracellu

158 moderate-transmission site, mefloquine had a protective efficacy of 38.1% (95% CI 11.8-56.5, p=0.008)

159 ompared in vitro and in vivo the potency and protective efficacy of 5C4 and the murine precursor of p

160 Protective efficacy of 63% (P = .03) and 88% (P = .002)

161 0.001 for uncomplicated malaria, indicating protective efficacy of 87.4% (95% CI: 79.6%, 92.2%) and

162 The objective was to evaluate the protective efficacy of a bivalent, recombinant vesicular

163 against Coxiella burnetii, we evaluated the protective efficacy of a formalin-inactivated C. burneti

164 ansgenic (HLA Tg) rabbit model to assess the protective efficacy of a human CD8(+) T cell epitope-bas

165 The immunogenicity and protective efficacy of a live attenuated vaccine consist

166 malaria-naive adults in order to define the protective efficacy of a malaria vaccine and thus guide

167 We evaluated the protective efficacy of a neutralizing monoclonal antibod

168 Here, we examined the immunogenicity and protective efficacy of a recombinant GBS BCP (rBCP), an

169 We investigated the scope for enhancing the protective efficacy of a single dose adenovirus-vectored

170 Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serot

171 e therefore evaluated the immunogenicity and protective efficacy of a single immunization of chimeric

172 We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with

173 In this study, we evaluated the protective efficacy of adenovirus serotype 26 (Ad26) vec

174 Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenz

175 used an aged mouse model to investigate the protective efficacy of an attenuated WNV, the nonstructu

176 respiratory tract, allowing us to assess the protective efficacy of an H5N1 LAIV against highly patho

177 ate its ability to significantly improve the protective efficacy of an inactivated influenza virus va

178 udy provides the very first evidence for the protective efficacy of an intravaginal microbicide/vacci

179 In germfree mice, there was no protective efficacy of antibody to PNAG due to the lack

180 ioluminescent imaging can be used to monitor protective efficacy of attenuated parasite immunizations

181 influences of PEM on the immunogenicity and protective efficacy of avian influenza A(H5N1) vaccine.

182 Our results demonstrate the striking protective efficacy of BcfA-mediated immunization, there

183 agonist c-di-AMP significantly enhanced the protective efficacy of BCG against pulmonary and extrapu

184 rculosis (M.tb.) challenge model to test the protective efficacy of BCG-disA-OE versus wild-type BCG

185 rial antigen Ag85A to boost may increase the protective efficacy of BCG.

186 ding candidate vaccine designed to boost the protective efficacy of BCG.

187 ting infection of mucosal tissues, while the protective efficacy of bnAbs targeting V1-V2 glycans (PG

188 ich combined the broad-spectrum activity and protective efficacy of both antibodies.

189 Recent studies have reported the protective efficacy of both natural(1) and vaccine-induc

190 he Salmonellagtr repertoire may confound the protective efficacy of broad-ranging Salmonella lipopoly

191 immunization approaches and help improve the protective efficacy of candidate HIV-1 vaccines.

192 current study, we examined the long-lasting protective efficacy of chimeric VLPs (cVLPs) containing

193 lonization to examine the immunogenicity and protective efficacy of EtpA.

194 s end, we demonstrate the immunogenicity and protective efficacy of FILORAB1, a recombinant, bivalent

195 the mouse model, we compared the inhibitory/protective efficacy of four mouse monoclonal antibodies

196 57BL/6 mice prior to challenge abrogated the protective efficacy of GCP-rCpa1 vaccine.

197 te the presence of Fc N-glycans enhances the protective efficacy of h-13F6, and that mAbs manufacture

198 We also evaluated the immunogenicity and protective efficacy of H5N1, H6N1, H7N3, and H9N2 ca vac

199 These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest

200 the CD4-mimetic compounds might increase the protective efficacy of HIV-1 vaccines.

201 re the animal model of choice for evaluating protective efficacy of HIV/SIV vaccine candidates and th

202 PD-1 also limited the protective efficacy of HMPV epitope-specific peptide vac

203 del for investigating the immunogenicity and protective efficacy of human CD8(+) T cell epitope-based

204 cine, in the present study, we evaluated the protective efficacy of ID93/GLA-SE as a boost to a BCG-p

205 y of SUDV mAbs were defined before assessing protective efficacy of individual mAbs using a mouse mod

206 me the antigenic variability and improve the protective efficacy of influenza vaccines, our research

207 The protective efficacy of influenza VLP vaccination was low

208 is study, we examined the immunogenicity and protective efficacy of influenza VLPs (H1N1 A/PR/8/34) a

209 ted role of the microbiota in modulating the protective efficacy of intranasal vaccination through th

210 tudy, we investigated the immunogenicity and protective efficacy of IpaB and IpaD administered intrad

211 We examined the immunogenicity and protective efficacy of IpaB and IpaD, alone or combined,

212 n in ferrets of the immunogenicity and cross-protective efficacy of isogenic mammalian cell-grown, li

213 and phenotypic specialization are linked to protective efficacy of memory T cells against reinfectio

214 We evaluated the immunogenicity and protective efficacy of MVA encoding influenza virus hema

215 onvalescent macaques partially abrogated the protective efficacy of natural immunity against rechalle

216 potential to improve the immunogenicity and protective efficacy of new and existing neonatal vaccine

217 ctive, and efficient method to determine the protective efficacy of new vaccines on pneumococcal colo

218 that the Hu-mouse can be used to predict the protective efficacy of novel tuberculosis vaccines/strat

219 Preclinical data showed partial protective efficacy of one of the short vaccine regimens

220 y effective in reducing HIV acquisition, the protective efficacy of oral tenofovir disoproxil fumarat

221 We aimed to assess the safety and protective efficacy of PfSPZ Vaccine against naturally a

222 Fc-dependent functions, did not abrogate the protective efficacy of PGT121 in 6 macaques.

223 hat AGMs can be useful for evaluation of the protective efficacy of pLAIV.

224 ipid moieties enhance the immunogenicity and protective efficacy of pneumococcal TH17 antigens throug

225 different VEEV immunogens and evaluated the protective efficacy of purified preparations of the resu

226 The immunogenicity and protective efficacy of purified RSV F nanoparticles was

227 These data demonstrate the protective efficacy of purified vaccine-elicited antivir

228 vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system.

229 n current study, we evaluated the safety and protective efficacy of recombinant unglycosylated RSV G

230 Here we explore the protective efficacy of replication-incompetent, recombin

231 activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines.

232 e represent an unexpected contributor to the protective efficacy of Salmonella vaccines outside the t

233 s may be a rapid approach for increasing the protective efficacy of seasonal vaccines in response to

234 However, the protective efficacy of such global HIV-1 vaccine antigen

235 To increase the protective efficacy of such monoclonal antibodies, we em

236 Here, we report the protective efficacy of Sudan virus (SUDV)- and Ebola vir

237 In this article, we review data for the protective efficacy of the 2 new rotavirus vaccines, wit

238 The protective efficacy of the DeltaBCG TK was tested in gui

239 end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against fou

240 To test this assumption, changes in the protective efficacy of the immune response to B. burgdor

241 We assessed the cross-protective efficacy of the malaria vaccine and inferred

242 The cross-variant protective efficacy of the P particle vaccine was compar

243 Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N

244 The protective efficacy of the recombinant vaccines, with or

245 udy, we evaluated in parallel the safety and protective efficacy of the RSV A2 recombinant unglycosyl

246 e current study, we evaluated the safety and protective efficacy of the RSV A2 recombinant unglycosyl

247 aluated the differential immune response and protective efficacy of the Sal-Ag vaccine against challe

248 clinical study in rhesus monkeys to test the protective efficacy of the shortened group 3 regimen.

249 However, the immunogenicity and protective efficacy of the three forms of F have not hit

250 om BCG without affecting the persistence and protective efficacy of the vaccine in cattle.

251 ion, the elicited antibody response, and the protective efficacy of the vaccines containing the DNA o

252 vaccine in pigs (60%) and to the homologous protective efficacy of the VLP vaccine in humans (47%).

253 s study was to assess the immunogenicity and protective efficacy of the VSV-SRV serotype 2 vaccine pr

254 tions in humans, including the assessment of protective efficacy of therapeutic interventions.

255 roteins and evaluated the immunogenicity and protective efficacy of these vaccine candidates in mice

256 The protective efficacy of this formulation in protecting Bt

257 The immunogenicity and protective efficacy of this novel vaccine were assessed

258 Immunogenicity and protective efficacy of three Campylobacter jejuni flagel

259 We compared the immunogenicity and protective efficacy of two mucosal/systemic vaccine regi

260 neumovax vaccine significantly increased the protective efficacy of vaccination in a lethal challenge

261 the Th17 adjuvant curdlan, and we tested the protective efficacy of vaccination in a murine model of

262 LR2/6, TLR3, and TLR9) greatly increased the protective efficacy of vaccination with an HIV envelope

263 esults provide tantalizing evidence that the protective efficacy of vaccine-elicited CD8(+) T cells m

264 e boosting antigen impacts the magnitude and protective efficacy of vaccine-elicited immune responses

265 However, the protective efficacy of vaccine-elicited polyclonal antib

266 tamin A deficiency on the immunogenicity and protective efficacy of vaccines has not been defined pre

267 osa pneumonia to assess the contributions to protective efficacy of various bacterial antigens and ho

268 Its long-term protective efficacy on primary liver cancer (PLC) and ot

269 Here, we evaluate the immunogenicity and protective efficacy (PE) of a refined and more stable ch

270 d with decreased risk of neonatal mortality (protective efficacy [PE] 18%, 95% CI 4-30; incidence rat

271 tected against moderate-to-severe diarrhoea (protective efficacy [PE] 75%, p=0.0070) and severe diarr

272 g concentrations (pharmacokinetics [PK]) and protective efficacy (pharmacodynamics [PD]).

273 ited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of p

274 neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of p

275 ed all ebolaviruses and demonstrated greater protective efficacy than ADI-15878 alone in EBOV-challen

276 For both measures of protective efficacy, the vaccine-microbicide combination

277 It induces modest levels of protective efficacy, thought to be mediated primarily by

278 adjuvants based on their immune profiles and protective efficacy to inform a rational development of

279 To compare its protective efficacy to that of VRC01 in vivo, we perform

280 ruses influenced HAI-specific antibodies and protective efficacy using a broadly protective vaccine c

281 ro effects on motility, opsonic killing, and protective efficacy using a mouse pneumonia model.

282 In this study, we present data on safety and protective efficacy using sporozoites with deletions of

283 ated whole-virus vaccines and compared their protective efficacy versus that of antigens from positiv

284 Protective efficacy was 58% (95% CI, 45%-67%, p<0.001) f

285 The protective efficacy was 70% against Shigella flexneri an

286 Protective efficacy was defined as 1-prevalence ratio or

287 Protective efficacy was dependent on dose and regimen.

288 ORTANCE The only HIV vaccine trial for which protective efficacy was detected correlated this efficac

289 Protective efficacy was determined by vaccination of BAL

290 Further protective efficacy was observed in immunized rabbits fo

291 bining R21 with TRAP-based viral vectors and protective efficacy was significantly enhanced.

292 imeric Plasmodium yoelii proteins to enhance protective efficacy, we designed PvRMC-CSP, a recombinan

293 While studying protective efficacy, we found unexpectedly that old (21-

294 Acquired immunity and protective efficacy were also assayed in the mouse lung

295 FdU) and examined their immunogenicities and protective efficacies when administered alone or followe

296 Several of our antibodies showed protective efficacy when tested in a novel murine challe

297 n, promoting thermal resilience and enhanced protective efficacy, which may be important in its use a

298 30, has since been shown to also demonstrate protective efficacy with a delayed treatment start.

299 tically test the putative epitopes for their protective efficacy with an ultimate goal of selecting t

300 Protective efficacy with microneedles was found to be si